W1507
W1507 is an NH2-TML-based linker-payload conjugate, in which the payload is Exatecan (HY-13631) and the linker is Mal-PEG4-Val-Ala-Ph-2,2-dimethylpropanoic acid (HY-184906). W1507 can be conjugated with Trastuzumab (HY-P9907) to synthesize the ADC Her2-W1507. Her2-W1507 exhibits in vivo anti-tumor activity. W1507 can be used for the research of gastric cancer, ovarian adenocarcinoma and Her2-amplified breast cancer.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 分子式: C61H75FN8O15
- 分子量:1179.29
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
Drug-Linker Conjugates for ADC アイソフォーム固有の製品をすべて表示
More
生物活性
W1507 (5 mM; 1 h) is resistant to cathepsin B-mediated cleavage, with no detectable Exatecan (HY-13631) release from the linker-payload in a cell-free in vitro assay[1].
Her2-W1507 (72 h) potently inhibits the proliferation of HER2-positive NCI-N87, SK-OV-3, and SK-BR-3 cells with IC50 values of 48.49 nM, 88.30 nM, and 65.22 nM respectively, while showing minimal activity against HER2-negative MDA-MB-231 cells (IC50 >500 nM) after 72 hours of incubation[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
化学情報
-
分子量 1179.29
-
分子式 C61H75FN8O15
-
SMILES
O=C(N[C@@H](C(C)C)C(N[C@@H](C)C(NC1=CC=CC=C1CC(C)(C)C(N[C@H]2CCC3=C4C2=C(CN5C(C(COC([C@@]6(CC)O)=O)=C6C=C57)=O)C7=NC4=CC(F)=C3C)=O)=O)=O)CCOCCOCCOCCOCCNC(CCN8C(C=CC8=O)=O)=O
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
純度とドキュメンテーション
参考文献
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
W1507 関連分類
HY-184905 関連分類
Powered by Bioz